The molecular physiology of uric acid homeostasis

Annual Review of Physiology

Volumn 77, Issue , 2015, Pages 323-345

  Mandal, Asim K ^a   Mount, David B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ABCG2; Hyperuricemia; SLC2A9; URAT1; Uric acid

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLUT9 PROTEIN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; NEUROHORMONE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PROTEIN SLC17A3; PROTEIN SLC17A4; PURINE DERIVATIVE; SODIUM; SODIUM PHOSPHATE COTRANSPORTER 1; UNCLASSIFIED DRUG; URATE; URATE TRANSPORTER; URIC ACID; ORGANIC ANION TRANSPORTER;

ABSORPTION; ARTICLE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; HYPERURICEMIA; INTESTINAL SECRETION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; MOLECULAR BIOLOGY; NONHUMAN; PDZ DOMAIN; PRIORITY JOURNAL; PURINE METABOLISM; ANIMAL; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; GENOME-WIDE ASSOCIATION STUDY; HOMEOSTASIS; HUMANS; HYPERURICEMIA; MOLECULAR BIOLOGY; ORGANIC ANION TRANSPORTERS; SIGNAL TRANSDUCTION; URIC ACID;

EID: 84922798458     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021113-170343     Document Type: Article

References (180)

1. Choi HK, Mount DB, Reginato AM. 2005. Pathogenesis of gout. Ann. Intern. Med. 143:499-516
2. Zhu Y, Pandya BJ, Choi HK. 2011. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63:3136-41
3. Singh JA, Strand V. 2008. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann. Rheum. Dis. 67:1310-16
4. Zhu Y, Pandya BJ, Choi HK. 2012. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am. J. Med. 125:679-87
5. Forman JP,ChoiH,CurhanGC. 2009. Uric acid and insulin sensitivity and risk of incident hypertension. Arch. Intern. Med. 169:155-62
6. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, et al. 2006. Uric acid and the development of hypertension: the normative aging study. Hypertension 48:1031-36
7. Feig DI, Soletsky B, Johnson RJ. 2008. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924-32
8. Doria A, Krolewski AS. 2011. Diabetes: lowering serum uric acid levels to prevent kidney failure. Nat. Rev. Nephrol. 7:495-96
9. Fam AG. 2002. Gout, diet, and the insulin resistance syndrome. J. Rheumatol. 29:1350-55
10. Choi HK, Ford ES, Li C, Curhan G. 2007. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 57:109-15
11. HooperDC, Spitsin S, Kean RB, Champion JM,DicksonGM, et al. 1998. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. PNAS 95:675-80
12. Spitsin S, Koprowski H. 2010. Role of uric acid in Alzheimer's disease. J. Alzheimers Dis. 19:1337-38
13. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. 2007. Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166:561-67
14. Ascherio A, LeWitt PA, Xu K, Eberly S,Watts A, et al. 2009. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66:1460-68
15. Peden DB, Hohman R, BrownME, Mason RT, Berkebile C, et al. 1990. Uric acid is a major antioxidant in human nasal airway secretions. PNAS 87:7638-42
16. Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, et al. 2013. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat. Genet. 45:145-54
17. Griebsch A, Zollner N. 1974. Effect of ribomononucleotides given orally on uric acid production in man. Adv. Exp. Med. Biol. 41:443-49
18. Ahmed M, Taylor W, Smith PR, Becker MA. 1999. Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J. Biol. Chem. 274:7482-88
19. Wu XW, Lee CC, Muzny DM, Caskey CT. 1989. Urate oxidase: primary structure and evolutionary implications. PNAS 86:9412-16
20. Wu XW, Muzny DM, Lee CC, Caskey CT. 1992. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol. 34:78-84
21. Ames BN, Cathcart R, Schwiers E, Hochstein P. 1981. Uric acid provides an antioxidant defense in humans against oxidant-And radical-caused aging and cancer: a hypothesis. PNAS 78:6858-62
22. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P. 1986. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J. 235:747-54
23. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, et al. 2002. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40:355-60
24. Oda M, Satta Y, Takenaka O, Takahata N. 2002. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol. Biol. Evol. 19:640-53
25. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. 2003. The association between gout and nephrolithiasis in men: the Health Professionals' Follow-Up Study. Kidney Int. 64:1022-26
26. Xu P, LaVallee PA, Lin JJ, Hoidal JR. 2004. Characterization of proteins binding to E-box/Ku86 sites and function of Ku86 in transcriptional regulation of the human xanthine oxidoreductase gene. J. Biol. Chem. 279:16057-63
27. Xu P, LaVallee P, Hoidal JR. 2000. Repressed expression of the human xanthine oxidoreductase gene. E-box and TATA-like elements restrict ground state transcriptional activity. J. Biol. Chem. 275:5918-26
28. Berry CE, Hare JM. 2004. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 555:589-606
29. Roch-Ramel F, Guisan B. 1999. Renal transport of urate in humans. News Physiol. Sci. 14:80-84
30. Guggino SE, Martin GJ, Aronson PS. 1983. Specificity and modes of the anion exchanger in dog renal microvillus membranes. Am. J. Physiol. Ren. Physiol. 244:F612-21
31. Martinez F, Manganel M, Montrose-Rafizadeh C, Werner D, Roch-Ramel F. 1990. Transport of urate and p-Aminohippurate in rabbit renal brush-border membranes. Am. J. Physiol. Ren. Physiol. 258:F1145-53
32. Roch-Ramel F, Diezi-Chomety F, De Rougemont D, Tellier M, Widmer J, Peters G. 1976. Renal excretion of uric acid in the rat: a micropuncture and microperfusion study. Am. J. Physiol. 230:768-76
33. Simmonds HA, Hatfield PJ, Cameron JS, Cadenhead A. 1976. Uric acid excretion by the pig kidney. Am. J. Physiol. 230:1654-61
34. Roch-Ramel F,Weiner IM. 1973. Excretion of urate by the kidneys of Cebus monkeys: amicropuncture study. Am. J. Physiol. 224:1369-74
35. Weiner IM. 1979. Urate transport in the nephron. Am. J. Physiol. 237:F85-92
36. Fanelli GM Jr, Bohn DL, Reilly SS. 1971. Renal urate transport in the chimpanzee. Am. J. Physiol. 220:613-20
37. Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, et al. 2010. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J. Am. Soc. Nephrol. 21:64-72
38. Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, et al. 2009. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci. Transl. Med. 1:5ra11
39. WoodwardOM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. 2009. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. PNAS 106:10338-42
40. Jutabha P, Anzai N, Kitamura K, Taniguchi A, Kaneko S, et al. 2010. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J. Biol. Chem. 285:35123-32
41. Diamond HS, Paolino JS. 1973. Evidence for a postsecretory reabsorptive site for uric acid in man. J. Clin. Investig. 52:1491-99
42. Guggino SE, Aronson PS. 1985. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J. Clin. Investig. 76:543-47
43. SteeleTH. 1973. Urate secretion in man: the pyrazinamide suppression test. Ann. Intern.Med. 79:734-37
44. Weiner IM, Tinker JP. 1972. Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention. J. Pharmacol. Exp. Ther. 180:411-34
45. Davis BB, Field JB, Rodnan GP, Kedes LH. 1965. Localization and pyrazinamide inhibition of distal transtubular movement of uric acid-2-C14 with a modified stop-flow technique. J. Clin. Investig. 44:716-21
46. Gutman AB, Yu TF. 1961. A three-component system for regulation of renal excretion of uric acid in man. Trans. Assoc. Am. Phys. 74:353-65
47. Steele TH, Boner G. 1973. Origins of the uricosuric response. J. Clin. Investig. 52:1368-75
48. Lemieux G, Vinay P, Gougoux A, Michaud G. 1973. Nature of the uricosuric action of benziodarone. Am. J. Physiol. 224:1440-49
49. Gutman AB, Yu TF, Berger L. 1959. Tubular secretion of urate in man. J. Clin. Investig. 38:1778-81
50. Blomstedt JW, Aronson PS. 1980. pH gradient-stimulated transport of urate and p-Aminohippurate in dog renal microvillus membrane vesicles. J. Clin. Investig. 65:931-34
51. Kahn AM, Aronson PS. 1983. Urate transport via anion exchange in dog renal microvillus membrane vesicles. Am. J. Physiol. Ren. Physiol. 244:F56-63
52. Kahn AM, Branham S,Weinman EJ. 1983. Mechanism of urate and p-Aminohippurate transport in rat renal microvillus membrane vesicles. Am. J. Physiol. Ren. Physiol. 245:F151-58
53. Werner D, Martinez F, Roch-Ramel F. 1990. Urate and p-Aminohippurate transport in the brush border membrane of the pig kidney. J. Pharmacol. Exp. Ther. 252:792-99
54. Roch-Ramel F,WernerD,Guisan B. 1994. Urate transport in brush-bordermembrane of human kidney. Am. J. Physiol. Ren. Physiol. 266:F797-805
55. Boner G, Steele TH. 1973. Relationship of urate and p-Aminohippurate secretion in man.Am. J. Physiol. 225:100-4
56. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, et al. 2002. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417:447-52
57. Mori K, Ogawa Y, Ebihara K, Aoki T, Tamura N, et al. 1997. Kidney-specific expression of a novel mouse organic cation transporter-like protein. FEBS Lett. 417:371-74
58. Hosoyamada M, Ichida K, Enomoto A, Hosoya T, Endou H. 2004. Function and localization of urate transporter 1 in mouse kidney. J. Am. Soc. Nephrol. 15:261-68
59. Uetake D, Ohno I, Ichida K, Yamaguchi Y, Saikawa H, et al. 2010. Effect of fenofibrate on uric acid metabolism and urate transporter Intern. Med. 49:89-94
60. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. 1992. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 42:333-35
61. Roch-Ramel F, Guisan B, Schild L. 1996. Indirect coupling of urate and p-Aminohippurate transport to sodium in human brush-border membrane vesicles. Am. J. Physiol. Ren. Physiol. 270:F61-68
62. Ichida K, Hosoyamada M, Hisatome I, Enomoto A,HikitaM, et al. 2004. Clinical andmolecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J. Am. Soc. Nephrol. 15:164-73
63. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, et al. 2004. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J. Pharmacol. Sci. 94:297-304
64. Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. 2007. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J. Am. Soc. Nephrol. 18:430-39
65. Bahn A, Hagos Y, Reuter S, Balen D, Brzica H, et al. 2008. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J. Biol. Chem. 283:16332-41
66. Schulz C, Fork C, Bauer T, Golz S, Geerts A, et al. 2014. SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem. J. 457:243-51
67. Tin A,Woodward OM, KaoWH, Liu CT, Lu X, et al. 2011. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum. Mol. Genet. 20:4056-68
68. FlynnTJ, Phipps-Green A, Hollis-Moffatt JE,MerrimanME, ToplessR, et al. 2013. Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects. Arthritis Res. Ther. 15:R220
69. Garcia ML, Benavides J, Valdivieso F. 1980. Ketone body transport in renal brush border membrane vesicles. Biochim. Biophys. Acta 600:922-30
70. Manganel M, Roch-Ramel F, Murer H. 1985. Sodium-pyrazinoate cotransport in rabbit renal brush border membrane vesicles. Am. J. Physiol. Ren. Physiol. 249:F400-8
71. Boumendil-Podevin EF, Podevin RA. 1981. Nicotinic acid transport by brush bordermembrane vesicles from rabbit kidney. Am. J. Physiol. Ren. Physiol. 240:F185-91
72. Goldfinger S, Klinenberg E Jr., Seegmiller JE. 1965. Renal retention of uric acid induced by infusion of beta-hydroxybutyrate and acetoacetate. N. Engl. J. Med. 272:351-55
73. Padova J, Bendersky G. 1962. Hyperuricemia in diabetic ketoacidosis. N. Engl. J. Med. 267:530-34
74. Lieber CS, Jones DP, Losowsky MS, Davidson CS. 1962. Interrelation of uric acid and ethanol metabolism in man. J. Clin. Investig. 41:1863-70
75. FanelliGMJr., Bohn D, Stafford S. 1970. Functional characteristics of renal urate transport in the Cebus monkey. Am. J. Physiol. 218:627-36
76. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. 2004. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277-81
77. Gibson HV, Doisy EA. 1923. A note on the effect of some organic acids upon the uric acid excretion of man. J. Biol. Chem. 55:605-10
78. Michael ST. 1944. The relation of uric acid excretion to blood lactic acid in man. Am. J. Physiol. 141:71-74
79. Harding VJ, Allin KD, Eagles BA. 1927. The influence of fat and carbohydrate diets upon the level of blood uric acid. J. Biol. Chem. 74:631-43
80. Drenick EJ. 1965. Hyperuricemia, acute gout, renal insufficiency and urate nephrolithiasis due to starvation. Arthritis Rheum. 8:988-97
81. Gershon SL, Fox IH. 1974. Pharmacologic effects of nicotinic acid on human purinemetabolism. J. Lab. Clin. Med. 84:179-86
82. Shapiro M, Hyde L. 1957. Hyperuricemia due to pyrazinamide. Am. J. Med. 23:596-99
83. Akalin E, Chandrakantan A, Keane J, Hamburger RJ. 2001. Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion. Am. J. Kidney Dis. 37:E8
84. Srinivas SR,Gopal E, Zhuang L, Itagaki S, Martin PM, et al. 2005. Cloning and functional identification of slc5a12 as a sodium-coupled low-Affinity transporter for monocarboxylates (SMCT2). Biochem. J. 392:655-64
85. CoadyMJ, ChangMH, Charron FM, PlataC,Wallendorff B, et al. 2004. The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J. Physiol. 557:719-31
86. Barac-Nieto M, Murer H, Kinne R. 1980. Lactate-sodium cotransport in rat renal brush border membranes. Am. J. Physiol. Ren. Physiol. 239:F496-506
87. Barbarat B, Podevin RA. 1988. Stoichiometry of the renal sodium-L-lactate cotransporter. J. Biol. Chem. 263:12190-93
88. Plata C, Sussman CR, Sindic A, Liang JO, Mount DB, et al. 2007. Zebrafish Slc5a12 encodes an electroneutral sodium monocarboxylate transporter (SMCTn). A comparison with the electrogenic SMCT (SMCTe/Slc5a8). J. Biol. Chem. 282:11996-2009
89. Thangaraju M, Ananth S, Martin PM, Roon P, Smith SB, et al. 2006. c/ebpδ null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J. Biol. Chem. 281:26769-73
90. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, et al. 2008. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet. 82:139-49
91. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, et al. 2008. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat. Genet. 40:430-36
92. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, et al. 2008. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat. Genet. 40:437-42
93. WeiW, Hemani G, Hicks AA, Vitart V, Cabrera-Cardenas C, et al. 2011. Characterisation of genomewide association epistasis signals for serum uric acid in human population isolates. PLOS ONE 6:e23836
94. Eraly SA, Vallon V, Rieg T, Gangoiti JA, Wikoff WR, et al. 2008. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol. Genomics 33:180-92
95. Augustin R, Carayannopoulos MO, Dowd LO, Phay JE, Moley JF, Moley KH. 2004. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): Alternative splicing alters trafficking. J. Biol. Chem. 279:16229-36
96. Kimura T, Takahashi M, Yan K, Sakurai H. 2014. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PLOS ONE 9:e84996
97. Bibee KP, Augustin R, Gazit V, Moley KH. 2013. The apical sorting signal for human GLUT9b resides in the N-terminus. Mol. Cell. Biochem. 376:163-73
98. Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, et al. 2009. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. PNAS 106:15501-6
99. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, et al. 2009. Mouse GLUT9: evidences for a urate uniporter. Am. J. Physiol. Ren. Physiol. 297:F612-19
100. Manolescu AR, Augustin R, Moley K, Cheeseman C. 2007. A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity. Mol. Membr. Biol. 24:455-63
101. Mandal A, Emerling DE, Serafini TA, Mount DB. 2011. Tranilast inhibits urate transport mediated by URAT1 and GLUT9. Am. Coll. Rheumatol. 62(Suppl. 10):164 (Abstr.)
102. Caulfield MJ,Munroe PB, O'Neill D, WitkowskaK,Charchar FJ, et al. 2008. SLC2A9 is a high-capacity urate transporter in humans. PLOS Med. 5:e197
103. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, et al. 2008. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J. Biol. Chem. 283:26834-38
104. Mandal AK, Mount DB. 2013. Transcriptional and translational heterogeneity of the SLC2A9 gene encoding the GLUT9 urate transporter. J. Am. Soc. Nephrol. 24:237A
105. Witkowska K, Smith KM, Yao SY, Ng AM, O'Neill D, et al. 2012. Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am. J. Physiol. Ren. Physiol. 303:F527-39
106. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, SnyderM. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489:57-74
107. Charles BA, Shriner D, Doumatey A, Chen G, Zhou J, et al. 2011. A genome-wide association study of serum uric acid in African Americans. BMC Med. Genomics 4:17
108. So A, Thorens B. 2010. Uric acid transport and disease. J. Clin. Investig. 120:1791-99
109. Merriman TR. 2011. Population heterogeneity in the genetic control of serum urate. Semin. Nephrol. 31:420-25
110. UranoW, Taniguchi A, Anzai N, Inoue E, Sekita C, et al. 2010. Association between GLUT9 and gout in Japanese men. Ann. Rheum. Dis. 69:932-33
111. Tu HP, Chen CJ, Tovosia S, Ko AM, Lee CH, et al. 2010. Associations of a non-synonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders. Ann. Rheum. Dis. 69:887-90
112. Hollis-Moffatt JE,GowPJ,Harrison AA, Highton J, Jones PB, et al. 2011. The SLC2A9 non-synonymous Arg265His variant and gout; evidence for a population-specific effect on severity. Arthritis Res. Ther. 13:R85
113. McArdle PF, Parsa A, Chang YP, Weir MR, O'Connell JR, et al. 2008. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in Old Order Amish. Arthritis Rheum. 58:2874-81
114. Phay JE, Hussain HB, Moley JF. 2000. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 66:217-20
115. Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. 2002. Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol. Int. 26:297-300
116. Shikhman AR, Brinson DC, Valbracht J, Lotz MK. 2001. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J. Immunol. 167:7001-8
117. Kimura T, Amonpatumrat S, Tsukada A, Fukutomi T, Jutabha P, et al. 2011. Increased expression of SLC2A9 decreases urate excretion from the kidney. Nucleosides Nucleotides Nucleic Acids 30:1295-301
118. Roch-Ramel F,Wong NL, Dirks JH. 1976. Renal excretion of urate in mongrel and Dalmatian dogs: a micropuncture study. Am. J. Physiol. 231:326-31
119. Friedman M, Byers SO. 1948. Observations concerning the causes of the excess excretion of uric acid in the Dalmatian dog. J. Biol. Chem. 175:727-35
120. Kahn AM, Shelat H, Weinman EJ. 1985. Urate and p-Aminohippurate transport in rat renal basolateral vesicles. Am. J. Physiol. Ren. Physiol. 249:F654-61
121. Werner D, Roch-Ramel F. 1991. Indirect Na+ dependency of urate and p-Aminohippurate transport in pig basolateral membrane vesicles. Am. J. Physiol. Ren. Physiol. 261:F265-72
122. Sweet DH, Chan LM, Walden R, Yang XP,Miller DS, Pritchard JB. 2003. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to theNa+ gradient.Am. J. Physiol. Ren. Physiol. 284:F763-69
123. Aslamkhan A, Han YH, Walden R, Sweet DH, Pritchard JB. 2003. Stoichiometry of organic anion/ dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am. J. Physiol. Ren. Physiol. 285:F775-83
124. Bakhiya A, Bahn A, Burckhardt G, Wolff N. 2003. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell. Physiol. Biochem. 13:249-56
125. Enomoto A, TakedaM, Shimoda M, Narikawa S, Kobayashi Y, et al. 2002. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J. Pharmacol. Exp. Ther. 301:797-802
126. Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I. 2010. Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biol. Pharm. Bull. 33:498-503
127. Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, et al. 2000. p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem. Biophys. Res. Commun. 270:254-59
128. Biber J,CusterM,WernerA,Kaissling B,Murer H. 1993. Localization ofNaPi-1, aNa/Pi cotransporter, in rabbit kidney proximal tubules. II. Localization by immunohistochemistry. Pflug. Arch. 424:210-15
129. UranoW, Taniguchi A, Anzai N, Inoue E, Kanai Y, et al. 2010. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann. Rheum. Dis. 69:1232-34
130. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, et al. 2008. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:1953-61
131. Togawa N, Miyaji T, Izawa S, Omote H, Moriyama Y. 2012.ANa+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am. J. Physiol. Cell Physiol. 302:C1652-60
132. Van Aubel RA, Smeets PH, Van Den Heuvel JJ, Russel FG. 2004. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Ren. Physiol. 288:F327-33
133. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. 2002. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13:595-603
134. Bataille AM, Goldmeyer J, Renfro JL. 2008. Avian renal proximal tubule epithelium urate secretion is mediated by Mrp4. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295:R2024-33
135. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. 2008. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein4Br. J. Pharmacol. 155:1066-75
136. Woodward OM, Tukaye DN, Cui J, Greenwell P, Constantoulakis LM, et al. 2013. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules. PNAS 110:5223-28
137. Rieselbach RE, SorensenLB, ShelpWD,SteeleTH. 1970. Diminished renal urate secretion per nephron as a basis for primary gout. Ann. Intern. Med. 73:359-66
138. Boss GR, Seegmiller JE. 1979. Hyperuricemia and gout. Classification, complications and management. N. Engl. J. Med. 300:1459-68
139. Perez-Ruiz F, CalabozoM, Erauskin GG, Ruibal A, Herrero-Beites AM. 2002. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 47:610-13
140. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, et al. 2012. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3:764
141. Matsuo H, Nakayama A, Sakiyama M, Chiba T, Shimizu S, et al. 2014. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci. Rep. 4:3755
142. Nakayama A, Matsuo H, Nakaoka H, Nakamura T, Nakashima H, et al. 2014. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Sci. Rep. 4:5227
143. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, et al. 2004. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-Anion exchanger URAT1 via its C-terminus. J. Biol. Chem. 279:45942-50
144. Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, et al. 2003. PDZK1. I. A major scaffolder in brush borders of proximal tubular cells. Kidney Int. 64:1733-45
145. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, et al. 2009. Meta-Analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLOS Genet. 5:e1000504
146. Cunningham R, Brazie M, Kanumuru S, E X, Biswas R, et al. 2007. Sodium-hydrogen exchanger regulatory factor-1 interacts with mouse urate transporter 1 to regulate renal proximal tubule uric acid transport. J. Am. Soc. Nephrol. 18:1419-25
147. Hoque MT, Conseil G, Cole SP. 2009. Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. Biochem. Biophys. Res. Commun. 379:60-64
148. Hoque MT, Cole SP. 2008. Down-regulation of Na+/H+ exchanger regulatory factor 1 increases expression and function of multidrug resistance protein Cancer Res. 68:4802-9
149. Park J, Kwak JO, Riederer B, Seidler U, Cole SP, et al. 2014. Na+/H+ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney. J. Am. Soc. Nephrol. 25:726-36
150. Wilkinson SP, Grove A. 2004. HucR, a novel uric acid-responsive member of the MarR family of transcriptional regulators from Deinococcus radiodurans. J. Biol. Chem. 279:51442-50
151. Perera IC,Grove A. 2010. Urate is a ligand for the transcriptional regulator PecS. J. Mol. Biol. 402:539-51
152. Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, et al. 2007. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude. Chest 131:1473-78
153. Wu W, Dnyanmote AV, Nigam SK. 2011. Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol. Pharmacol. 79:795-805
154. Maesaka JK, Fishbane S. 1998. Regulation of renal urate excretion: a critical review. Am. J. Kidney Dis. 32:917-33
155. Pascual E, Perdiguero M. 2006. Gout, diuretics and the kidney. Ann. Rheum. Dis. 65:981-82
156. Weinman EJ, EknoyanG, SukiWN. 1975. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J. Clin. Investig. 55:283-91
157. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. 1993. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 270:354-59
158. Page LB, Damon A, Moellering RC Jr. 1974. Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation 49:1132-46
159. Egan BM, Lackland DT. 2000. Biochemical and metabolic effects of very-low-salt diets.Am. J. Med. Sci. 320:233-39
160. Masugi F, Ogihara T, Hashizume K, Hasegawa T, Sakaguchi K, Kumahara Y. 1988. Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J. Hum. Hypertens. 1:293-98
161. DelRio A, Rodriguez-Villamil JL. 1993. Metabolic effects of strict salt restriction in essential hypertensive patients. J. Intern. Med. 233:409-14
162. Skrabal F, Aubock J,HortnaglH. 1981. Low sodium/high potassium diet for prevention of hypertension: probable mechanisms of action. Lancet 2:895-900
163. Ruppert M, Diehl J, Kolloch R, Overlack A, Kraft K, et al. 1991. Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults. Klin.Wochenschr. 69(Suppl. 25):51-57
164. Deleted in proof
165. Ferris TF, Gorden P. 1968. Effect of angiotensin and norepinephrine upon urate clearance in man. Am. J. Med. 44:359-65
166. Moriwaki Y, Yamamoto T, Tsutsumi Z, Takahashi S, Hada T. 2002. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism 51:893-95
167. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. 2001. Effect of norepinephrine on the urinary excretion of purine bases and oxypurinol. Metabolism 50:1230-33
168. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, et al. 2004. Uric acid and the state of the intrarenal renin-Angiotensin system in humans. Kidney Int. 66:1465-70
169. AbikoH,Konta T, Hao Z,Takasaki S, SuzukiK, et al. 2009. Factors correlated with plasma renin activity in general Japanese population. Clin. Exp. Nephrol. 13:130-37
170. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. 1991. Relationship between resistance to insulinmediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008-11
171. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, et al. 1995. Effect of insulin on uric acid excretion in humans. Am. J. Physiol. Endocrinol. Metab. 268:E1-5
172. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, et al. 1996. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am. J. Hypertens. 9:746-52
173. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. 1997. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin. Sci. 92:51-58
174. Choi HK, Ford ES. 2007. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am. J. Med. 120:442-47
175. Christensson T. 1977. Serum urate in subjects with hypercalcaemic hyperparathyroidism. Clin. Chim. Acta 80:529-33
176. Miller PD, Schwartz EN,Chen P,Misurski DA, Krege JH. 2007. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos. Int. 18:59-68
177. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, et al. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344:1434-41
178. Hui JY, Choi JW, Mount DB, Zhu Y, Zhang Y, Choi HK. 2012. The independent association between parathyroid hormone levels and hyperuricemia: a national population study. Arthritis Res. Ther. 14:R56
179. Ayvazian JH, Ayvazian IF. 1963. Changes in serum and urinary uric acid with the development of symptomatic gout. J. Clin. Investig. 42:1835-39
180. UranoW, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y, et al. 2002. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J. Rheumatol. 29:1950-53